Karen Lisa Smith, Hua-Ling Tsai, David Lim, Chenguang Wang, Raquel Nunes, Mary J Wilkinson, Jennifer Y Sheng, Rima Couzi, John Fetting, Carol Riley, Antonio C Wolff, Cesar A Santa-Maria, Katie Papathakis, Lauren Collins-Chase, Christie Hilton, Elissa Thorner, Amanda Montanari, Dara Ikejiani, Claire Snyder, Vered Stearns
PURPOSE: Treatment-associated symptoms drive early discontinuation of adjuvant endocrine therapy (ET) for breast cancer. We hypothesized that symptom monitoring with electronic patient-reported outcomes (ePROs) during adjuvant ET will enhance symptom detection, symptom management, and persistence. METHODS: Eligible patients were initiating ET for stage 0-III breast cancer. Participants completed ePRO surveys via smartphone at baseline and 1, 3, 6, and 12 months...
September 21, 2023: JCO oncology practice
Deborah B Ejem, Stephen Wechsler, Sarah Gallups, Sarah Khalidi, Jazmine Coffee-Dunning, Aoyjay P Montgomery, Courtney J Stevens, Kimberly Keene, Gabrielle B Rocque, Mary Chamberlin, Mark T Hegel, Andres Azuero, Maria Pisu, Daphne Ellis, Stacey A Ingram, Valerie M Lawhon, Tiffany Gilbert, Kali Morrissette, Jamme Morency, Karen Thorp, Megan Codini, Robin Newman, Jennifer Echols, Danielle Cloyd, Sarah Dos Anjos, Colleen Muse, Susan Goedeken, Kristen Elizabeth Laws, Jennae Herbert, Marie Bakitas, Kathleen D Lyons
PURPOSE: Evidence supporting social media-based recruitment of cancer survivors is limited. This paper describes how we used Facebook during the COVID-19 pandemic to augment our recruitment of breast cancer survivors for our two-site telephone-based randomized clinical trial (RCT) at Dartmouth-Hitchcock Medical Center and the University of Alabama at Birmingham. METHODS: Originally a two-site RCT of a telephone-delivered breast cancer survivorship intervention, we extended our clinic-based recruitment to Facebook...
September 21, 2023: JCO oncology practice
Syn Kok Yeo, Michael Haas, Kanakaraju Manupati, Mingang Hao, Fuchun Yang, Song Chen, Jun-Lin Guan
Most breast cancers do not respond to immune checkpoint inhibitors and there is an urgent need to identify novel sensitization strategies. Herein, we uncovered that activation of the TBK-IFN pathway that is mediated by the TBK1 adapter protein AZI2 is a potent strategy for this purpose. Our initial observations showed that RB1CC1 depletion leads to accumulation of AZI2, in puncta along with selective macroautophagy/autophagy cargo receptors, which are both required for TBK1 activation. Specifically, disrupting the selective autophagy function of RB1CC1 was sufficient to sustain AZI2 puncta accumulation and TBK1 activation...
September 21, 2023: Autophagy
Cintia Melo Sousa, Izabella Nobre Queiroz, Ana Paula Drummond-Lage
PURPOSE: Assess the local recurrence rate and global survival rate among women diagnosed with breast cancer who underwent intraoperative electron radiotherapy (IOERT) between 2007 and 2017, in a single private healthcare setting in Belo Horizonte, Brazil. MATERIAL AND METHODS: This is a retrospective study based on medical records about the outcomes of patients submitted to breast-conserving surgery followed by IOERT. The collected variables included the patient's profile and tumor features, IOERT isodose, and outcomes...
September 21, 2023: International Journal of Radiation Biology
Andrea Joaquin Garcia, Mattia Rediti, David Venet, Samira Majjaj, Roswitha Kammler, Elisabetta Munzone, Lorenzo Gianni, Beat Thürlimann, István Láng, Marco Colleoni, Sherene Loi, Giuseppe Viale, Meredith M Regan, Laurence Buisseret, Françoise Rothé, Christos Sotiriou
PURPOSE: To explore whether specific triple-negative breast cancer (TNBC) molecular subtypes are predictive for a benefit from maintenance low-dose cyclophosphamide and methotrexate (CM) in the adjuvant IBCSG 22-00 phase III clinical trial. EXPERIMENTAL DESIGN: RNA sequencing was performed on a selection of 347 TNBC FFPE tumor samples following a case-cohort-like sampling. TNBC subtypes were computed on gene expression data. The association between TNBC subtypes and treatment outcome was assessed using a Cox proportional-hazard interaction test...
September 21, 2023: Clinical Cancer Research
Xu Cao, Kristen E Muller, Mary D Chamberlin, Jiang Gui, Peter A Kaufman, Gary N Schwartz, Roberta M DiFlorio-Alexander, Brian W Pogue, Keith D Paulsen, Shudong Jiang
PURPOSE: The aim of this study is to investigate whether Near-Infrared Spectral Tomography (NIRST) might serve as a reliable prognostic tool to predict Residual Cancer Burden (RCB) in breast cancer patients undergoing neoadjuvant chemotherapy (NAC) based upon early treatment response measurements. EXPERIMENTAL DESIGN: A total of thirty-five breast cancer patients receiving NAC were included in this study. NIRST imaging was performed at multiple time points, including: before treatment, at end of the first cycle, at the mid-point, and post-NAC treatments...
September 21, 2023: Clinical Cancer Research
Anastasiia Morozova, Claudia Cotes, Shima Aran, Harnoor Singh
Emergencies in breast imaging are infrequent but not rare. Although infectious conditions such as mastitis and breast abscess are the most common breast diseases encountered in acute care settings, other entities that may require additional imaging or different treatment approaches are also seen and include traumatic injury and breast cancer. While mammography is widely available for breast evaluation in outpatient facilities, most emergency departments do not have mammography units. This makes evaluation of patients with breast disease incomplete in the acute care setting and emphasizes the role of appropriate US techniques for interpretation...
October 2023: Radiographics: a Review Publication of the Radiological Society of North America, Inc
Beatriu Reig, Eric Kim, Chloe M Chhor, Linda Moy, Alana A Lewin, Laura Heacock
Breast MRI has high sensitivity and negative predictive value, making it well suited to problem solving when other imaging modalities or physical examinations yield results that are inconclusive for the presence of breast cancer. Indications for problem-solving MRI include equivocal or uncertain imaging findings at mammography and/or US; suspicious nipple discharge or skin changes suspected to represent an abnormality when conventional imaging results are negative for cancer; lesions categorized as Breast Imaging Reporting and Data System 4, which are not amenable to biopsy; and discordant radiologic-pathologic findings after biopsy...
October 2023: Radiographics: a Review Publication of the Radiological Society of North America, Inc
Suahn Jang Cho, Yan Tian
This study investigates the relationship between media use and breast cancer screening intentions by integrating the celebrity identification model and the theory of reasoned action. It tests an integrative model with survey data from 315 U.S. adult women. The study found that media use for breast cancer information was positively associated with parasocial interaction (PSI) and identification with celebrities who have or have had breast cancer; PSI was positively associated with attitudes, descriptive and injunctive norms in breast cancer screening, while identification with celebrities was positively associated with descriptive norms; attitudes, injunctive norms and descriptive norms were positively associated with breast cancer screening intentions...
September 21, 2023: Health Communication
Oreste Davide Gentilini, Edoardo Botteri, Claudia Sangalli, Viviana Galimberti, Mauro Porpiglia, Roberto Agresti, Alberto Luini, Giuseppe Viale, Enrico Cassano, Nickolas Peradze, Antonio Toesca, Giulia Massari, Virgilio Sacchini, Elisabetta Munzone, Maria Cristina Leonardi, Francesca Cattadori, Rosa Di Micco, Emanuela Esposito, Adele Sgarella, Silvia Cattaneo, Massimo Busani, Massimo Dessena, Anna Bianchi, Elisabetta Cretella, Francisco Ripoll Orts, Michael Mueller, Corrado Tinterri, Badir Jorge Chahuan Manzur, Chiara Benedetto, Paolo Veronesi
IMPORTANCE: Sentinel lymph node biopsy (SLNB) is the standard of care for axillary node staging of patients with early breast cancer (BC), but its necessity can be questioned since surgery for examination of axillary nodes is not performed with curative intent. OBJECTIVE: To determine whether the omission of axillary surgery is noninferior to SLNB in patients with small BC and a negative result on preoperative axillary lymph node ultrasonography. DESIGN, SETTING, AND PARTICIPANTS: The SOUND (Sentinel Node vs Observation After Axillary Ultra-Sound) trial was a prospective noninferiority phase 3 randomized clinical trial conducted in Italy, Switzerland, Spain, and Chile...
September 21, 2023: JAMA Oncology
Seema A Khan
No abstract text is available yet for this article.
September 21, 2023: JAMA Oncology
Mariam Al-Muftah, Fares Al-Ejeh
BACKGROUND: Arab countries are projecting increase in cancer incidence and mortality, however, there are limited studies that compare the epidemiology of cancer in Arab countries compared to other parts of the world. METHODS: We used the 2018 Global Cancer Observatory data to compare the age-standardized incidence and mortality estimates in Arab-speaking countries to the rest of the world. RESULTS: Rates for incidence and mortality for all cancers in Arab countries were lower than the world's rates but the incidence rates of non-Hodgkin and Hodgkin lymphoma, bladder, breast, and liver cancers were higher...
September 21, 2023: Cancer Epidemiology, Biomarkers & Prevention
Sarah Prinsloo, Ted J Kaptchuk, Dirk De Ridder, Randall Lyle, Eduardo Bruera, Diane Novy, Carlos H Barcenas, Lorenzo G Cohen
BACKGROUND: Chemotherapy-induced peripheral neuropathy (CIPN) includes negative sensations that remain a major chronic problem for cancer survivors. Previous research demonstrated that neurofeedback (a closed-loop brain-computer interface [BCI]) was effective at treating CIPN versus a waitlist control (WLC). The authors' a priori hypothesis was that BCI would be superior to placebo feedback (placebo control [PLC]) and to WLC in alleviating CIPN and that changes in brain activity would predict symptom report...
September 21, 2023: Cancer
Tomonori Yoshida, Munenori Ide, Kazuhisa Katayama, Mitsuhiro Yanai, Ryo Kurosaki, Hisashi Shimizu, Kazuhisa Arakawa, Tatsuya Miyazaki, Hiroshi Saeki, Ken Shirabe
The metastasis of breast cancer to the gastrointestinal tract is rare. Herein, we presented the case of an 85-year-old woman who had a history of invasive lobular carcinoma and experienced complete colon rupture due to relatively low-energy trauma. The patient underwent bilateral total mastectomy and axillary dissection following preoperative chemotherapy 6 years ago. She had a local recurrence 2 years after the surgery and underwent chemotherapy. Subsequently, the cancer metastasized to the thoracolumbar area and retroperitoneum...
September 21, 2023: Clinical Journal of Gastroenterology
Ayako Bun, Masayuki Nagahashi, Mamiko Kuroiwa, Miki Komatsu, Yasuo Miyoshi
PURPOSE: Eribulin is a unique anti-cancer drug which can improve overall survival (OS) of patients with metastatic breast cancer (MBC), probably by modulating the tumor immune microenvironment. The aim of this study was to investigate the clinical significance of serum levels of immune-related and inflammatory cytokines in patients treated with eribulin. Furthermore, we investigated the association between cytokines and immune cells, such as myeloid-derived suppressor cells (MDSCs) and cytotoxic and regulatory T cells, to explore how these cytokines might affect the immune microenvironment...
September 21, 2023: Breast Cancer Research and Treatment
Ana Heredia, Benjamín Walbaum, María Vidal, Laura Itriago, Mauricio Camus, Francisco Dominguez, Manuel Manzor, Raúl Martínez, Geraldine Murature, Sabrina Muñiz, Marisel Navarro, Constanza Guerra, Tomas Merino, Lidia Medina, Carolina Ibañez, Karol Ramirez, Francisco Acevedo, César Sánchez
PURPOSE: The incidence of breast cancer in young women (BCYW) has increased in recent decades. Malignant disease in this subset is characterized by its aggressiveness and poor prognosis. Ovarian function suppression (OFS) in these patients improves survival especially in hormone receptor-positive (HR +) cases. The Regan Composite Risk (RCR) is a prognostic tool to identify high-risk HR + BC candidates for OFS. Our study sought to characterize a Chilean cohort of early HR + BCYW assessing the use of OFS and its related prognosis and the utility of RCR in our patients...
September 21, 2023: Breast Cancer Research and Treatment
Tadafumi Shimizu, Takaaki Oba, Masanori Oshi, Ken-Ichi Ito
PURPOSE: Chemotherapeutic agents exert immunomodulatory effects on triple-negative breast cancer (TNBC) cells and immune cells. Eribulin favorably affects the immunological status of patients with breast cancer. However, the effects of eribulin on the immune cells remain unexplored. The aim of this study was to investigate the effects of eribulin on immune cells. METHODS: Peripheral blood mononuclear cells (PBMCs) from healthy donors and mouse splenocytes were stimulated with anti-CD3 and anti-CD28 antibodies...
September 21, 2023: Breast Cancer Research and Treatment
Alexandra R Harris, Gatikrushna Panigrahi, Huaitian Liu, Vishal N Koparde, Maeve Bailey-Whyte, Tiffany H Dorsey, Clayton C Yates, Stefan Ambs
African American (AA) women have an excessive risk of developing triple-negative breast cancer (TNBC). We employed ATAC-sequencing to characterize differences in chromatin accessibility between 9 commonly used TNBC cell lines derived from patients of European and African ancestry. Principal component and chromosome mapping analyses of accessibility peaks with the most variance revealed separation of chromatin profiles by patient group. Motif enrichment and footprinting analyses of disparate open chromatin regions revealed differences in transcription factor activity, identifying 79 with ancestry-associated binding patterns (FDR < 0...
September 21, 2023: Cancer Res Commun
Sandeep Ghosh, Bonny Joseph, Amar Jain, Sanjay M Desai, Vinod Dhakad, Soumya Singh
INTRODUCTION: In the realm of oncology, the development of TIVAD (chemoport) has been a blessing for cancer patients, freeing them from having to undergo numerous recurrent venepunctures throughout their treatment. The External Jugular Vein cut-down has been the standard procedure for administering chemotherapy to cancer patients at our institution. Here, we discuss our experience with the External Jugular Vein cut-down Chemoport Insertion Technique and the outcomes it produced. MATERIALS AND METHODS: We performed a prospective observational study and included all patients who underwent the open External Jugular Vein cut-down technique of Chemoport Insertion from January 2019 to January 2022 in the Department of Surgical Oncology at our hospital...
September 2023: Gulf Journal of Oncology
Abdullah Alsuhaibani, Abdul Rahman Alqahtani, Abdulaziz Alsaif, Areej Bokhari, Basel AlMefleh, Yara Aldigi, Tareq Salah
INTRODUCTION: 85-90% of local recurrences after breastconserving surgery occurs within the index quadrant. Intraoperative radiotherapy may be a good alternative for eligible patients avoiding long course of adjuvant radiation. PATIENTS AND METHODS: Eligible patients were early stage node negative at least 50 years at time of inclusion, unicentric less than 30mm in diameter any hormone receptor status. 21 Gy was delivered intraoperatively, biologically equivalent to 58 to 60 Gy in standard fractionation using electron beam to 90% isodose line...
September 2023: Gulf Journal of Oncology
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read

Save your favorite articles in one place with a free QxMD account.


Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.